Reneo Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RPHM research report →
About the company
Reneo Pharmaceuticals, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to creating therapies for individuals suffering from uncommon inherited mitochondrial disorders. The company's lead candidate, REN001, functions as a selective peroxisome proliferator-activated receptor delta agonist.
- CEO
- Gregory J. Flesher
- IPO
- 2021
- Employees
- 8
- HQ
- Irvine, CA, US
Price Chart
- Market Cap
- $60.84M
- P/E
- -4.21
- P/S
- 0.00
- P/B
- 1.35
- EV/EBITDA
- 9.69
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 0.00%
- Revenue
- $0 · 0.00%
- Net Income
- $0 · 0.00%
- EPS
- $-4.40 · 0.00%
- Op Income
- $-62,950,000
- FCF YoY
- -1.38%
- 52W High
- $82.90
- 52W Low
- $1.68
- 50D MA
- $14.92
- 200D MA
- $16.09
- Beta
- 0.22
- Avg Volume
- 17.98K
Get TickerSpark's AI analysis on RPHM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 25, 24 | Leonard Braden Michael | buy | 68,746 |
| Sep 24, 24 | Leonard Braden Michael | buy | 29,600 |
| Sep 18, 24 | Leonard Braden Michael | buy | 806 |
| Sep 17, 24 | Leonard Braden Michael | buy | 55,300 |
| Sep 16, 24 | Leonard Braden Michael | buy | 172,747 |
| Sep 13, 24 | Leonard Braden Michael | buy | 150,000 |
| Sep 12, 24 | Leonard Braden Michael | buy | 36,176 |
| Aug 14, 24 | Leonard Braden Michael | buy | 100,487 |
| Aug 13, 24 | Leonard Braden Michael | buy | 171,339 |
| May 14, 24 | Leonard Braden Michael | buy | 335,000 |
Our RPHM coverage
Recent articles, reports, and earnings notes.
No research on RPHM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RPHM report →Similar companies
Peers in the same neighborhood.